In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild ...

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer’s disease (early AD) ...

The European Commission on Tuesday authorized the use of Eisai and Biogen's drug to treat some patients with mild cognitive ...

European regulators on Tuesday authorized the use of Biogen and Eisai’s Alzheimer’s treatment Leqembi for some early-stage ...

Stockholm, April 15, 2025 - The European Commission has today communicated that it has granted BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai's application for Marketing Authorization ...

This summary of health news briefs includes reports on how the U.S.-China trade war impacts drug costs, EU approval of ...

The antibody lecanemab is the first authorized therapy in Europe that targets the underlying process of Alzheimer's, rather than only treating symptoms.

The European Commission has for the first time approved an Alzheimer's therapy that targets the underlying disease processes.

The European Commission has approved the antibody lecanemab to treat Alzheimer's, the first time it has authorized a therapy which targets the underlying disease processes, rather than just the ...

WASHINGTON, April 15, 2025 (GLOBE NEWSWIRE) -- According to national security advisor and legal strategist Jim Rickards, America may be days away from opening what he calls the country's "greatest ...